OncLive TV

Scott T. Tagawa, MD, FASCO, FACP, MS, discusses the addition of lutetium 177Lu-rosopatamab tetraxetan to SOC in mCRPC.

Jessica Paulus, ScD, explains the rationale for utilizing an external control arm in a single-arm phase 2 HER2-positive metastatic breast cancer trial.

Mitchell Parma, MD, discusses an analysis of survival benefit with immunotherapy in patients with NSCLC brain metastases.

Alicia Morgans, MD, MPH, discusses health-related quality of life outcomes with darolutamide plus ADT in patients with mHSPC.

Nagi S. El-Saghir, MD, FACP, FASCO, discusses ribociclib plus endocrine therapy in premenopausal HR-positive breast cancer by liver metastases status.

Alexey Danilov, MD, PhD, discusses the significance of a manuscript that was published following the first Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Jeremy Abramson, MD, discusses the use of glofitamab with gemcitabine and oxaliplatin in patients with relapsed/refractory DLBCL.

Niels van de Donk, MD, discusses initial safety and efficacy findings from the first-in-human study of JNJ-5322 in relapsed or refractory multiple myeloma.

Paolo Ghia, MD, PhD, discusses the efficacy of fixed-duration ibrutinib plus venetoclax in patients with CLL/SLL.

Kelsey Pan, MD, MPH, highlights the utilization of tarlatamab in real-world patients with SCLC ineligible for the phase 2 DeLLphi-301 trial.

Robin Jones, MD, MRCP, discusses the treatment armamentarium for patients with gastrointestinal stromal tumors.

Daniel DeAngelo, MD, PhD, shares the rationale behind a meta analysis of asparaginase regimens vs hyper‐CVAD in adult and AYA patients with ALL.

Expert investigators in GI cancers share their perspectives on the most significant updates in the space shared during the 2025 ASCO Annual Meeting.

Paolo Tarantino, MD, discusses the evolving role of trastuzumab plus pertuzumab and chemotherapy in HER2-positive breast cancer after DESTINY-Breast09.

Dirk Arnold, MD, PhD, on the investigation of amivantamab vs cetuximab, both in combination with chemotherapy, in RAS/BRAF wild-type mCRC.

Maurie Markman, MD, discussed the significance of patient-reported outcomes from the phase 3 OUTBACK trial in locally advanced cervical cancer.

Christine Chung, MD, contextualizes efficacy data with ficerafusp alfa plus pembrolizumab within the larger treatment paradigm for HPV-negative HNSCC.

Amitkumar Mehta, MD, details the FDA approval of tafasitamab with rituximab and lenalidomide for relapsed/refractory follicular lymphoma.

Massimo Cristofanilli, MD, discusses the next steps with camizestrant in ESR1-mutated HR-positive, HER2-negative advanced breast cancer.

C. Ola Landgren, MD, PhD, discussed the benefit of Dara-KRd in patients with multiple myeloma stratified by transplant eligibility, risk, and age.

Rami Komrokji, MD, shares results from a pooled analysis of outcomes with imetelstat based on prior therapy in transfusion-dependent lower-risk MDS.

Kate Gasparini, PharmD, BCOP, BCPPS, discusses issues with administering oral agents in pediatric patients with cancer or patients with dysphagia.

Yi Lin, MD, PhD, discusses the rationale for evaluating the onset of delayed toxicities following cilta-cel infusion in patients with multiple myeloma.

Jessica Paulus, ScD, discusses findings from a real-world, retrospective analysis of factors contributing to early-onset CRC.

Linda R. Duska, MD, MPH, discusses the need for continued research with concurrent chemoradiation in high-risk advanced cervical cancer.

Alan Tan, MD, emphasizes the importance of considering safety profiles and patient-related factors before selecting an IO regimen in metastatic ccRCC.

Jason S. Starr, DO, discusses DLL3 as a treatment target in extrapulmonary neuroendocrine carcinomas.

Gina Z. D’Amato, MD, shares her interpretation of efficacy outcomes from the negative Alliance A092104 trial in advanced uterine leiomyosarcoma.

Tahla Munir, MBChB, PhD, details the efficacy of first-line zanubrutinib and clinical implications for treatment selection in CLL.

Rana R. McKay, MD, FASCO, discusses data the combination of olaparib plus radium-223 vs radium-223 monotherapy in castration-resistant prostate cancer.